Protalix is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx plant cell-based protein expression system. The Company's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of Gaucher's Disease. The Company has concluded phase III studies for this drug and is currently undergoing FDA review. Treatment is currently being provided by Protalix to Gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide.